CD19 and prostate carcinoma: Here, eight NSG mice were engrafted s.c. with 22Rv1 prostate cancer cells, and treated with i.v. injection of STEAP1 CAR T cells (N = 3), CD19 CAR T cells (N = 2), or NT T cells (N = 3).